Nuo Therapeutics Changes Auditors to EisnerAmper LLP
Ticker: AURX · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1091596
| Field | Detail |
|---|---|
| Company | Nuo Therapeutics, Inc. (AURX) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, financial-reporting
TL;DR
Nuo Therapeutics swapped auditors from WithumSmith+Brown to EisnerAmper, effective June 6, 2024.
AI Summary
Nuo Therapeutics, Inc. announced on June 7, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, WithumSmith+Brown, PC, effective June 6, 2024. Nuo Therapeutics has appointed EisnerAmper LLP as its new independent registered public accounting firm.
Why It Matters
A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors should monitor.
Risk Assessment
Risk Level: medium — Changes in auditors can sometimes precede or coincide with financial restatements or other disclosures that may impact stock price.
Key Players & Entities
- Nuo Therapeutics, Inc. (company) — Registrant
- WithumSmith+Brown, PC (company) — Former certifying accountant
- EisnerAmper LLP (company) — New certifying accountant
- June 7, 2024 (date) — Date of report
- June 6, 2024 (date) — Effective date of dismissal
FAQ
When was the dismissal of the former auditor effective?
The dismissal of WithumSmith+Brown, PC was effective June 6, 2024.
Who is Nuo Therapeutics' new independent registered public accounting firm?
Nuo Therapeutics has appointed EisnerAmper LLP as its new independent registered public accounting firm.
Did the former auditor report any disagreements with Nuo Therapeutics?
The filing states that there were no disagreements or reportable events with the former auditor, WithumSmith+Brown, PC.
Has Nuo Therapeutics requested the former auditor to prepare a letter addressed to the SEC?
Yes, Nuo Therapeutics has requested that the former auditor furnish a letter addressed to the SEC stating whether it is in agreement with the statements made by the registrant in response to Item 4.01.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 7, 2024.
Filing Stats: 940 words · 4 min read · ~3 pages · Grade level 14.2 · Accepted 2024-06-11 16:26:06
Filing Documents
- aurx20240606_8k.htm (8-K) — 28KB
- ex_686753.htm (EX-16.1) — 5KB
- b01.jpg (GRAPHIC) — 8KB
- b02.jpg (GRAPHIC) — 4KB
- b03.jpg (GRAPHIC) — 8KB
- 0001437749-24-019961.txt ( ) — 184KB
- noticker-20240607.xsd (EX-101.SCH) — 3KB
- noticker-20240607_def.xml (EX-101.DEF) — 10KB
- noticker-20240607_lab.xml (EX-101.LAB) — 14KB
- noticker-20240607_pre.xml (EX-101.PRE) — 11KB
- aurx20240606_8k_htm.xml (XML) — 3KB
01. Changes in Registrant ' s Certifying Accountant
Item 4.01. Changes in Registrant ' s Certifying Accountant. (a) Effective June 7, 2024 (the "Effective Date"), Nuo Therapeutics, Inc. (the "Company") dismissed Marcum LLP ("Marcum") as the Company's independent registered public accounting firm. Marcum (and its predecessor firm GBH CPAs PC) had served as the Company's independent public accountants since September 27, 2017. The decision to change accountants was made by the Audit Committee of the Board of Directors of the Company. The reports of Marcum on the audits of the consolidated financial statements of the Company as of and for the years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles except that such report contained explanatory paragraphs in respect to uncertainty as to the Company's ability to continue as a going concern. During the Company's fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through the date of this Current Report on Form 8-K, there were (i) no disagreements (as such term is used in Item 304(a)(1)(iv) of Regulation S-K) between the Company and Marcum on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreement(s), if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreement(s) in connection with its report on the Company's financial statements, or (ii) reportable events as that term is defined in Item 304(a)(1)(v) of Regulation S-K except the material weaknesses discussed below. . In connection with its audit of, and in the issuance of its reports on the Company's consolidated financial statements for the years ended December 31, 2023 and 2022, Marcum advised and the Company's management concurred with the following items to be material weaknesses in the effectiveness of t
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER DESCRIPTION 16.1 Letter from Marcum LLP to Securities and Exchange Commission dated June 11, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuo Therapeutics, Inc. By: /s/ David E. Jorden David E. Jorden Chief Executive and Financial Officer Date: June 11, 2024